Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab

@inproceedings{Horneff2016ComparisonOT,
  title={Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab},
  author={Gerd Horneff and Ariane Klein and Jens Klotsche and Kirsten Minden and H I Huppertz and Frank Weller-Heinemann and Jasmin Beate Kuemmerle-Deschner and J Peter Haas and Anton Hospach},
  booktitle={Arthritis research & therapy},
  year={2016}
}
BACKGROUND Treatment response, remission rates and compliance in patients with polyarticular juvenile idiopathic arthritis (polyJIA) treated with adalimumab, etanercept, or tocilizumab were analyzed in clinical practice. METHODS Data collected in the German BIKER registry were analyzed in patients with polyJIA who started treatment with approved biologics, adalimumab, etanercept or tocilizumab, from 2011 to 2015. Baseline patient characteristics, treatment response, safety and drug survival… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…